PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).Xuewei Ding, Han Liang, Mingzhi Cai et al.|Journal of Clinical Oncology|2023Cited by 30
Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial.Xuewei Ding, Han Liang, Bin Li et al.|Journal of Clinical Oncology|2022Cited by 14
CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC).Qiang Xue, Han Liang, Baogui Wang et al.|Journal of Clinical Oncology|2021Cited by 6
151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)Qian‐Li Xue, Han Liang, B. Wang et al.|Annals of Oncology|2021Cited by 3
Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage <scp>IV</scp> gastric cancerYong Liu, Han Liang, Qiang Xue et al.|International Journal of Cancer|2025Cited by 3